mevastatin has been researched along with geranylgeraniol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Croucher, PI; Helfrich, MH; Rogers, MJ; Russell, RG; Shipman, CM | 1 |
| Bosia, A; Campia, I; Ghigo, D; Lussiana, C; Pescarmona, G; Riganti, C | 1 |
2 other study(ies) available for mevastatin and geranylgeraniol
| Article | Year |
|---|---|
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Lovastatin; Mevalonic Acid; Multiple Myeloma; Protein Prenylation; Tumor Cells, Cultured | 1998 |
Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis.
Topics: Cell Death; Cell Line, Tumor; Cell Proliferation; Cholesterol; Diterpenes; Electron Transport; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mitochondria; Monocytes; Terpenes; Ubiquinone | 2009 |